Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients

Hepatology International

Volumn 6, Issue 1, 2012, Pages 397-402

  Rana, S V ^a   Ola, R P ^a   Sharma, Sanjeev K ^a   Arora, S K ^a   Sinha, S K ^a   Pandhi, P ^a   Singh, K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Hepatotoxicity; Isoniazid; N acetyltransferase 2; Slow and fast acetylator

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; SERUM ALBUMIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; FEMALE; FLUOROMETRY; FOLLOW UP; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; N ACETYLTRANSFERASE 2 GENE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TOXIC HEPATITIS; TUBERCULOSIS;

EID: 84862869146     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9309-4     Document Type: Article

References (30)

1. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995;333: 11-18
2. Hwang SJ, Lee CN, Yen FS, et al. A prospective clinical study of isoniazid-rifampcin-pyrazinamide induced liver injury in an area endemic for hepatitis. Br J Gastroenterol Hepatol 1997;12: 87-92
3. Tariq S, Khan TS, Malik S, Anwar MS, Rashid A. Frequency of anti-tuberculous therapy-induced hepaptotoxicity in patients and their outcome. J Ayub Med Coll Abbottabad 2009;21: 50-52
4. Huang YS, Chern HD, Su WJ, et al. CytochromeP4502E1 genotype susceptibility to anti-tuberculosis drug induced hepatitis. Herpetology 2003;37: 924-930
5. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992;27: 337-384
6. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976;84: 181-192
7. Farrell GC. Drug-induced acute hepatitis. In Farrell GC, editor. Drug-induced liver disease. Churchill Livingstone: Edinburgh; 1994. 247-99.
8. Ryan DE, Ramanathan L, Iida S, et al. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Bio Chem 1985;260: 6385-6393
9. Tao L, Xiang YB, Wang R, et al. Environmental tobacco smoke in relation to bladder cancer risk-the Shanghai bladder cancer study. Cancer Epidemiol Biomarkers Prev 2010;19: 3087-3095
10. Rabstein S, Brüning T, Harth V, et al. N-acetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptordefined breast cancer. Eur J Cancer Prev 2010;19: 100-109
11. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolizing enzyme polymorphism and predisposition to anti-tuberculosis drug induced liver injury: a meta-analysis. Int J Tuberc lung Dis 2008; 12: 994-1002
12. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of anti-tuberculosis drug-induced hepatitis. Hepatology 2002;35: 883-889
13. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996;51: 132-136
14. Benichou C. Criteria of drug induced liver disorders: reform of international consensus meeting. J Hepatol 1990;11: 272-276
15. Sud K, Muthukumar T, Singh B, et al. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients. Methods Find Exp Clin Pharmacol 2000;22: 647-649
16. Scott EM, Wright RC. Fluorimetric determination of isonicotinic acid hydrazide in serum. J Lab Clin Med 1967;70: 353-360
17. Neughaur S, BabaT Watanabe T, Ishizaki T, Kurokawa K. An early risk marker for diabetic nephropathy in Japanese type 2 diabetic patients. Diabetic Med 1994;11: 783-788
18. Suzuki H, Morris JS, Li Y, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008;29: 1184-1191
19. Rana SV, Pal R, Vaiphei K, Ola RP, Singh K. Hepatoprotection by carotenoids in isoniazid-rifampicin induced hepatic injury in rats. Biochem Cell Biol 2010;88: 819-834
20. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989;42: 157-234
21. Mahmood K, Hussain A, Jairmani KL, et al. Hepatotoxicity with anti-tuberculosis drugs: the risk factors. Pak J Med Sci 2007;23: 33-38
22. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of INH and RMP induced hepatotoxicity. Intl J Tuberc Lung Dis 2000;4: 256-261
23. Doll Ma, Fretland AJ, Deitz AC, Hein W. Determination of human NAT2 acetylator genotype by restriction fragment length polymorphism and allele- specific amplification. Anal Biochem 1995;231: 413-418
24. Freguson RJ, Doll MA, Rustan TD, Gray K, Hein DW. Cloning, expression and functional characterization of two mutant (NAT2-191and NAT2-341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metabol Dispos 1994;22: 371-376
25. Parthasarthy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercule 1986;67: 99-108
26. Gurumurthi P, Kirshnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984;129: 58-61
27. Vatsis KP, Weber WW, Bel DA, et al. Nomenclature for Nacetyltransferase genetic polymorphism of cytochrome P4502E1 in Swedish population. Relationship to incidence of lung cancer. Pharmacogenesis 1995;5: 1-20
28. Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic Nacetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterology and Hepatology 2011;26: 312-318
29. Díaz-Molina R, Cornejo-Bravo JM, Ramos-Ibarra MA. Genotypye and phenotype of NAT2 and the occurrence of adverse drug reaction in Mexican individuals to an isonizid-based prophylactic chemotherapy for tuberculosis. Mol Med Rep 2008;1: 875-879
30. Singh N, Dubey S, Chinnaraj S, Golani A, Maitra A. Study of NAT2 gene polymorphisms in an Indian population: associationwith plasma isoniazid concentration in a cohort of tuberculosis patients. Mol Diag Ther 2009;13: 49-58